AML

Tapan Kadia, MD, discusses the recent and upcoming changes in treatment of acute myeloid leukemia for patients who are not candidates for intensive remission induction therapy.

Following impressive data presented at the ASH Annual Meeting, the FDA granted approval to olutasidenib or the treatment of patients with treatment-naïve and relapsed or refractory acute myeloid leukemia.

Brian Jonas, MS. PhD, discusses e-selection as a biomarker in acute myeloid leukemia, and how e-selectin inhibition works along with chemotherapy to decrease tumor growth.

Melhem M. Solh, MD, discusses results of a study investigating allogeneic stem cell transplant in patients with myelodysplastic syndrome and acute myeloid leukemia with a TP53 mutation, previously presented at the 2022 Transplantation & Cellular Therapy Meetings.

Treatment with olutasidenib induced durable remissions and a manageable adverse event profile in patients with relapsed/refractory acute myeloid leukemia who harbor IDH1 mutations.

Adding magrolimab to azacytidine and venetoclax led to a rate of high responses in high-risk de novo and secondary acute myeloid leukemia.

Comparing intensive remission induction chemotherapy prior to allogeneic hematopoietic cell transplantation to watchful waiting followed by sequential conditioning did not show superior results.

Salvage chemotherapy after lintuzumab-Ac225 showed promising early efficacy results in patients with relapsed/refractory acute myeloid leukemia by eliminating residual leukemia cells.

In an interview with Targeted Oncology, Tapan M. Kadia, MD, discussed e-selection inhibition, and other novel targets for acute myeloid leukemia therapy.

Tapan Kadia, MD, discusses potential improvements to lower intensity therapy for less fit patients with acute myeloid leukemia.

Eprenetapopt combined with azacitidine as maintenance therapy after hematopoietic stem-cell transplant induced encouraging relapse-free and overall survival in patients with TP53-mutant acute myeloid leukemia and myelodysplastic syndrome.

Positive and durable complete responses observed with olutasidenib in adult patient with relapsed or refractory acute myeloid leukemia and a susceptible IDH1 mutation have led the FDA to grant approval to the drug for this group of patients

Eytan M. Stein, MD, discusses the currently available treatment options for patients with acute myeloid leukemia and how Menin inhibitors fit into this space.

Closing out their discussion, Drs Hetty Carraway and Eytan M. Stein highlight an ongoing clinical trial investigating a triplet therapy for AML.

Dr Stein explains clinical trial data on the use of magrolimab plus azacitidine for patients with TP53-mutated AML.

Dr Carraway highlights some of the most urgent unmet needs for patients with higher-risk MDS.

Eytan M. Stein, MD, discusses how to treat patients with MDS who have IDH or TP53 mutations, and whether there is a role for targeted therapy in this patient population.

The phase 1 study of lintuzumab-Ac225 combined with the CLAG-M regimen in acute myeloid leukemia demonstrated positive response rates, including an overall survival rate of 53% at 1-year and 32% at 2-years.

Eytan M. Stein, MD, defines Menin inhibition and its role in the leukemia space.

According to results from the SIERRA trial, Iomab-B may be an effective choice for patient with relapsed or refractory acute myeloid leukemia who are 55 years of age or older.

Dr Hetty Carraway muses on whether magrolimab plus azacitadine will be used as a standard treatment for higher-risk MDS in the future.

Drs Stein and Carraway explain the rationale for a magrolimab and azacitidine combination treatment for patients with higher-risk MDS with supporting data from 2 clinical trials.

The FDA has released their final guidance for developing drugs and biological products for the treatment of patients with acute myeloid leukemia. This focuses on the end points in which sponsors and clinicians should consider when looking at these new agents.

In an interview with Targeted Oncology, Eytan M. Stein, MD, discussed the benefits and potential use of menin inhibition for patients with acute myeloid leukemia.

Based on data from the phase 3 QuANTUM-First trial, the FDA has accepted and granted priority review to the new drug application for quizartinib for patients with FLT3-ITD-positive acute myeloid leukemia.